Developer docs
API playgroundTry for free, no card

Search company profiles

Cellbox Labs

Full company profile

uuid0000ov6

Namestring
Cellbox Labs
Legal namestring
Cellboxlabs SIA
Websiteurl
cellboxlabs.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Cellbox Labs is a Latvian deep-tech startup headquartered in Riga that develops and commercializes industrial organ-on-chip (OoC) technology for pharmaceutical, biotechnology, and academic customers. Founded in 2020 by Gatis Mozolevskis (CEO), Roberts Rimsa (CTO), and Arturs Abols (CSO), the company has built a team of approximately 17 PhD-level researchers, engineers, and project managers bridging microfluidics, cell biology, and precision manufacturing.

The company's core offering is a vertically integrated platform comprising three components: (1) the Dynamic Organ Chip — a mass-manufacturable, PDMS-free COC (cyclic olefin copolymer) chip with stacked endothelial/epithelial channels and a permeable membrane supporting up to four organs per chip; (2) the Automated System — an instrument with a modular manifold (8 to 24 chips), proprietary pumping, integrated bright-field microscopy for real-time monitoring, embedded software for remote experiment design, and controlled gas environments for hypoxia modeling; and (3) Contract Research Services — tailored experimental protocols, feasibility studies, and model development for intestinal, cancer, vasculature, and microbiome applications using primary cells, iPSCs, and patient-derived organoids. A BSL3-compatible cultivation system has been filed for patent.

Cellbox Labs monetizes through direct enterprise sales of hardware (chips and instruments) priced via custom quotation, alongside contract research services. Revenue is supplemented — but not principally driven — by EU non-dilutive grant funding through programs including IPCEI (€3.3M, 2025), Eurostars, and ERDF. The go-to-market motion is enterprise field sales activated through scientific conference presence (MPS World Summit, SLAS, EUROoCS, WORD+, CSEM) and a website-driven "Get a Quote" funnel, with no channel partner or reseller distribution. As of mid-2025 the company is operating with roughly €4.2M cumulative funding, one patent pending, and recognition including the Latvian Startup Award (IMPACT, 2024) and EIT Health Catapult semi-finalist status.

Short descriptiontext

Cellbox Labs is a Riga-based deep-tech company (founded 2020) that develops and sells industrialized organ-on-chip platforms — mass-manufactured COC chips, automated cultivation instruments, and contract research services — to pharmaceutical, biotechnology, and academic customers for drug testing, disease modeling, and toxicology.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRiga, Latvia
HQ citystring
Riga
HQ countrystring
Latvia
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
organ-on-chip technology, microfluidics devices, drug testing platforms, in vitro tissue models, automated lab instruments
Industry2 codes
PRIMARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAGAIAG
Cell Culture & Bioprocess Lab Equipment (Bioreactors, Single-Use Systems, Controllers)
NAICS code3 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Surgical and Medical Instrument Manufacturing339112
SIC code4 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Services-Commercial Physical & Biological Research8731
  • Laboratory Analytical Instruments3826
  • Laboratory Apparatus & Furniture3821
Product category
Organ-on-chip instruments and consumables
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Organ-on-Chip Hardware Products
TypeHardware Sales
Description

Sale of mass-manufactured COC chip devices and automated cultivation instruments (Dynamic Organ Chip, Automated System with manifold). Products are sold directly to pharmaceutical, biotech, and academic customers for drug testing, disease modeling, and research applications.

cellboxlabs.com
2Contract Research Services
TypeProfessional Services
Description

Tailored experimental protocols and feasibility studies performed by Cellbox Labs scientific team. Services cover in vitro pharmacology (PK/PD studies, toxicity and efficacy testing), host-microbiota interaction studies, biological barrier transport and integrity testing, and disease modeling. Uses primary cells, cancer cell lines, patient-derived cells, iPS-derived cells, and co-cultures.

cellboxlabs.com
3EU Research Grants and Project Funding
TypeLicensing Royalties
Description

Company participates in multiple EU-funded research projects (IPCEI, Eurostars, ERDF,Competence Centre) that provide project-based funding for technology development and validation. This supports R&D but represents non-dilutive funding rather than commercial revenue.

labsoflatvia.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Pricing details1 tier
1Custom Quote-Based Pricing
ModelOtherBilling cadenceMulti-year contract
Notes

All products and services appear to be priced via custom quotation. The company website features a 'Get a Quote' contact form for interested customers. No public price list is available.

cellboxlabs.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Cellbox Labs designs, mass-manufactures, and sells an integrated industrial organ-on-chip platform consisting of mass-produced COC chip devices and an automated cultivation instrument with integrated real-time microscopy, software, and proprietary pumping and gas-control systems. The company also delivers tailored contract research services covering in vitro pharmacology, disease modeling, and feasibility studies using primary cells, iPSC-derived cells, organoids, and co-cultures for pharmaceutical, biotech, and academic customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Automated system captures images of entire channel in just 2 minutes
+4 more records
Product overview1 text field

Cellbox Labs offers an industrial organ-on-chip platform consisting of three integrated components: the Dynamic Organ Chip (mass-manufacturable chips with vertically stacked channel design), the Automated System (instrument with modular manifold expandable from 8 to 24 chips), and Contract Research Services. The platform combines microfluidics with living cells to recreate tissue-specific microenvironments for drug testing, cancer research, and toxicology applications. All components are designed to work together as a unified system with integrated real-time microscopy and software control.

Product and service3 records
1Dynamic Organ Chip
CategoryOrgan-on-chip consumables
Description

A mass-manufactured, dynamic organ-on-chip device with a vertically stacked channel design that separates endothelial and epithelial channels via a permeable membrane. Made from COC (cyclic olefin copolymer) instead of PDMS, the chips are single-use and EtO-sterilized, with selectable membrane pore sizes and porosities. Supports integration of up to four organs on a single chip and is sold to pharmaceutical, biotech, and academic customers for drug testing, disease modeling, and toxicology applications.

2Automated System
CategoryLab automation instruments
Description

An automated cultivation instrument with a modular manifold expandable from 8 to 24 chips, providing controlled flow, gas environment, and integrated bright-field microscopy for real-time monitoring. The system includes embedded software for flexible experiment design, automatic full-channel image capture in approximately 2 minutes, and remote monitoring from office or home. Designed for user-friendly operation with a target of a few hours of training and no prior microfluidics experience required, and is sold to pharmaceutical, biotech, and academic customers.

3Contract Research Services
CategoryContract research services
Description

Tailored experimental protocols, feasibility studies, optimization, and proof-of-concept testing performed by the Cellbox Labs scientific team, using the company's organ-on-chip platform with established intestinal, cancer, and vasculature models. Services cover in vitro pharmacology including PK/PD studies, toxicity and efficacy testing, host-microbiota interaction studies, biological barrier transport and integrity testing, and disease modeling, using primary cells, cancer cell lines, patient-derived cells, iPS-derived cells, and co-cultures. Sold to pharmaceutical, biotech, and academic customers.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership16 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-06-01
Description

PHARMIDEA is the cooperation partner in the COMPETE project (Project No. 1.1.1.3/1./24/A/157), focused on comparing organ-on-chip versus traditional systems for Ozempic generic quality assessment. Project period June 2025 to May 2027, costs €873,448.

2BMC (Biomedical Research & Study Centre)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-05-01
Description

BMC is the Principal Investigator host institution for the DIGI-MET2D project (Project No. 1.1.1.3/1./24/A/043, costs €656,455), with Dr. Ilze Elbere as PI. Project focuses on precision metformin dosing using digital twin and gut-on-a-chip models for Type 2 Diabetes patients.

cellboxlabs.com
3ESQlabs
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-05-01
Description

ESQlabs was contracted under the DIGI-MET2D project for digital twin model development, as part of the project's approach to integrating digital twin simulations with organ-on-chip technology for personalized Type 2 Diabetes treatment.

cellboxlabs.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-05-01
Description

Listed as cooperation partner in the MIRACLE project (Project No. 1.1.1.3/1./24/A/156, €855,505, May 2025–April 2027), focused on real-time multi-modal monitoring platform for organ-on-chip models integrating optical sensors and impedance spectroscopy.

5Dr. Maira Elksne Research Group
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-05-01
Description

Led by Dr. Maira Elksne, this collaboration in the Real-time electrochemical detection project (Project No. 1.1.1.3/1./24/A/052, €677,328, May 2025–April 2028) aims to develop electrochemical sensor technology for continuous ATP and glucose monitoring in organ-on-chip systems.

cellboxlabs.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-04-01
Description

KTH Royal Institute of Technology is a project partner in the GBA-Connect project (Eureka Eurostars 5304, period April 2024–March 2026, €250,000), alongside Latvian Biomedical Research & Study Centre, Teadusmosaiik OÜ, and Fewer Moving Parts Ltd. Focus on vascularized Gut-Brain-Axis-on-chip platform.

7Teadusmosaiik OÜ
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-04-01
Description

Listed as a partner in the GBA-Connect Eurostars project (project No. 5304, €250,000, April 2024–March 2026).

cellboxlabs.com
8Fewer Moving Parts Ltd
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-04-01
Description

Listed as a partner in the GBA-Connect Eurostars project (project No. 5304, €250,000, April 2024–March 2026).

cellboxlabs.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner on the Cellbox Labs website's 'Our Partners' section. The partnership involves advancing frontiers of scientific discovery in cell research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Listed as a partner on the Cellbox Labs website. Altis Biosystems is referenced in the VALIDATE project as the source of high-quality primary small intestinal cells for the industrial-grade Gut-on-a-Chip platform. Also listed as a company logo partner on the Cellbox Labs website.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner on the Cellbox Labs website. KTH is also a project partner in GBA-Connect (Eureka Eurostars project 5304), collaborating on the vascularized Gut-Brain-Axis-on-chip platform.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner on the Cellbox Labs website. Embion is the project coordinator of the HARMONIS Eurostars project (6525), focused on microbiome optimization and nutrition for healthy ageing.

13BMC (Biomedical Research Centre)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner on the Cellbox Labs website. BMC (Latvian Biomedical Research & Study Centre) is a key collaborator in multiple EU projects including LoCBox, PERFORM-CHIP, PROCEX, COMPETE, VALIDATE, DIGI-MET2D, and GBA-Connect.

cellboxlabs.com
14CFI
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner on the Cellbox Labs website 'Our Partners' section.

cellboxlabs.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner on the Cellbox Labs website. University of Latvia's Institute of Solid State Physics is a project partner in the MIRACLE project and LoCBox project.

16Max Delbrück Center for Molecular Medicine
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner on the Cellbox Labs website 'Our Partners' section.

cellboxlabs.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Emulate is the leading commercial organ-on-chip company, offering the Emulate Chip-A1 and associated instruments. Direct competitor in the same OoC product category targeting pharma and biotech customers; significantly larger and more commercially mature.

TypeDirect peer
Description

MIMETAS provides organ-on-chip platforms (OrganoPlate) for compound screening and disease modeling, with a strong focus on high-throughput applications. Directly comparable product offering for pharma and biotech preclinical researchers.

3CN Bio
TypeDirect peer
Description

CN Bio offers PhysioMimix organ-on-chip systems for drug discovery and disease modeling, including liver, lung, and gut models. Comparable hardware-plus-consumables OoC platform serving pharma R&D customers.

TypeDirect peer
Description

TissUse develops multi-organ-chip (MOC) platforms enabling interconnection of multiple organ models. Comparable OoC technology targeting drug testing and ADME applications.

TypeDirect peer
Description

Hesperos produces human-on-a-chip multi-organ systems for toxicity and efficacy testing, particularly serving orphan disease and rare disease drug development. Comparable OoC service-and-platform model.

TypeDirect peer
Description

SynVivo offers microfluidic organ-on-chip platforms for drug delivery and toxicity studies, including tumor and BBB models. Comparable product offering and customer base in pharma and academic research.

TypeEmerging player
Description

InSphero provides 3D cell culture models and organoids for drug discovery, with overlap in disease modeling and toxicology. Comparable target customer base, though focuses on static 3D models rather than microfluidic OoC platforms.

TypeBroad incumbent
Description

Organovo is an early pioneer in 3D bioprinted human tissue for preclinical research and therapeutic applications. Broader incumbent in tissue engineering space with adjacent but different technology approach.

TypeEmerging player
Description

Bi/ond develops organ-on-chip platforms with focus on scalable and reproducible in vitro models for pharma applications. Comparable emerging European OoC start-up with overlapping customer focus.

TypeOthers
Description

Altis Biosystems provides primary intestinal epithelial cell models and is a named partner of Cellbox Labs on the VALIDATE project. Adjacent ecosystem participant supplying biological inputs for Cellbox's gut-on-chip platform.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cellbox Labs

Organ-on-chip instruments and consumablescellboxlabs.com

Cellbox Labs is a Riga-based deep-tech company (founded 2020) that develops and sells industrialized organ-on-chip platforms — mass-manufactured COC chips, automated cultivation instruments, and contract research services — to pharmaceutical, biotechnology, and academic customers for drug testing, disease modeling, and toxicology.

What Cellbox Labs does

Cellbox Labs is a Latvian deep-tech startup headquartered in Riga that develops and commercializes industrial organ-on-chip (OoC) technology for pharmaceutical, biotechnology, and academic customers. Founded in 2020 by Gatis Mozolevskis (CEO), Roberts Rimsa (CTO), and Arturs Abols (CSO), the company has built a team of approximately 17 PhD-level researchers, engineers, and project managers bridging microfluidics, cell biology, and precision manufacturing.

The company's core offering is a vertically integrated platform comprising three components: (1) the Dynamic Organ Chip — a mass-manufacturable, PDMS-free COC (cyclic olefin copolymer) chip with stacked endothelial/epithelial channels and a permeable membrane supporting up to four organs per chip; (2) the Automated System — an instrument with a modular manifold (8 to 24 chips), proprietary pumping, integrated bright-field microscopy for real-time monitoring, embedded software for remote experiment design, and controlled gas environments for hypoxia modeling; and (3) Contract Research Services — tailored experimental protocols, feasibility studies, and model development for intestinal, cancer, vasculature, and microbiome applications using primary cells, iPSCs, and patient-derived organoids. A BSL3-compatible cultivation system has been filed for patent.

Cellbox Labs monetizes through direct enterprise sales of hardware (chips and instruments) priced via custom quotation, alongside contract research services. Revenue is supplemented — but not principally driven — by EU non-dilutive grant funding through programs including IPCEI (€3.3M, 2025), Eurostars, and ERDF. The go-to-market motion is enterprise field sales activated through scientific conference presence (MPS World Summit, SLAS, EUROoCS, WORD+, CSEM) and a website-driven "Get a Quote" funnel, with no channel partner or reseller distribution. As of mid-2025 the company is operating with roughly €4.2M cumulative funding, one patent pending, and recognition including the Latvian Startup Award (IMPACT, 2024) and EIT Health Catapult semi-finalist status.

Cellbox Labs firmographics

Firmographics
Name
Cellbox Labs
Legal name
Cellboxlabs SIA
Website
https://cellboxlabs.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Cellbox Labs is a Riga-based deep-tech company (founded 2020) that develops and sells industrialized organ-on-chip platforms — mass-manufactured COC chips, automated cultivation instruments, and contract research services — to pharmaceutical, biotechnology, and academic customers for drug testing, disease modeling, and toxicology.
Ownership category
akta.pro rank

Cellbox Labs industry classification

Industry
Product category
Organ-on-chip instruments and consumables
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841), Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826), Laboratory Apparatus & Furniture (3821)
akta.pro industry
PRIMARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAGAIAG
Cell Culture & Bioprocess Lab Equipment (Bioreactors, Single-Use Systems, Controllers)

Keywords

  • Organ-on-chip technology
  • Microfluidics devices
  • Drug testing platforms
  • In vitro tissue models
  • Automated lab instruments

Where Cellbox Labs is headquartered

Location

Headquarters

HQ city
Riga
HQ country
Latvia
HQ region
Europe

Offices1 record

Markets served

Cellbox Labs business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Organ-on-Chip Hardware Products: Sale of mass-manufactured COC chip devices and automated cultivation instruments (Dynamic Organ Chip, Automated System with manifold). Products are sold directly to pharmaceutical, biotech, and academic customers for drug testing, disease modeling, and research applications.
  2. Contract Research Services: Tailored experimental protocols and feasibility studies performed by Cellbox Labs scientific team. Services cover in vitro pharmacology (PK/PD studies, toxicity and efficacy testing), host-microbiota interaction studies, biological barrier transport and integrity testing, and disease modeling. Uses primary cells, cancer cell lines, patient-derived cells, iPS-derived cells, and co-cultures.
  3. EU Research Grants and Project Funding: Company participates in multiple EU-funded research projects (IPCEI, Eurostars, ERDF,Competence Centre) that provide project-based funding for technology development and validation. This supports R&D but represents non-dilutive funding rather than commercial revenue.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom Quote-Based Pricing

Go-to-market motion3 records

Distribution channels1 record

Marketing channels6 records

Cellbox Labs product offering

Product offering

Core offering

Cellbox Labs designs, mass-manufactures, and sells an integrated industrial organ-on-chip platform consisting of mass-produced COC chip devices and an automated cultivation instrument with integrated real-time microscopy, software, and proprietary pumping and gas-control systems. The company also delivers tailored contract research services covering in vitro pharmacology, disease modeling, and feasibility studies using primary cells, iPSC-derived cells, organoids, and co-cultures for pharmaceutical, biotech, and academic customers.

Product overview

Cellbox Labs offers an industrial organ-on-chip platform consisting of three integrated components: the Dynamic Organ Chip (mass-manufacturable chips with vertically stacked channel design), the Automated System (instrument with modular manifold expandable from 8 to 24 chips), and Contract Research Services. The platform combines microfluidics with living cells to recreate tissue-specific microenvironments for drug testing, cancer research, and toxicology applications. All components are designed to work together as a unified system with integrated real-time microscopy and software control.

Differentiator

Problem solved

Functional benefit

Products and services

  • Dynamic Organ Chip A mass-manufactured, dynamic organ-on-chip device with a vertically stacked channel design that separates endothelial and epithelial channels via a permeable membrane. Made from COC (cyclic olefin copolymer) instead of PDMS, the chips are single-use and EtO-sterilized, with selectable membrane pore sizes and porosities. Supports integration of up to four organs on a single chip and is sold to pharmaceutical, biotech, and academic customers for drug testing, disease modeling, and toxicology applications.
  • Automated System An automated cultivation instrument with a modular manifold expandable from 8 to 24 chips, providing controlled flow, gas environment, and integrated bright-field microscopy for real-time monitoring. The system includes embedded software for flexible experiment design, automatic full-channel image capture in approximately 2 minutes, and remote monitoring from office or home. Designed for user-friendly operation with a target of a few hours of training and no prior microfluidics experience required, and is sold to pharmaceutical, biotech, and academic customers.
  • Contract Research Services Tailored experimental protocols, feasibility studies, optimization, and proof-of-concept testing performed by the Cellbox Labs scientific team, using the company's organ-on-chip platform with established intestinal, cancer, and vasculature models. Services cover in vitro pharmacology including PK/PD studies, toxicity and efficacy testing, host-microbiota interaction studies, biological barrier transport and integrity testing, and disease modeling, using primary cells, cancer cell lines, patient-derived cells, iPS-derived cells, and co-cultures. Sold to pharmaceutical, biotech, and academic customers.

Quantifiable outcome

  • Automated system captures images of entire channel in just 2 minutes
  • +4 more outcomes

Companies that use Cellbox Labs

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Cellbox Labs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature7 records

Cellbox Labs partnerships and signals

Strategic signal

Partnerships

16 partnerships are on record, tiered minor and core.

  • PHARMIDEAminorStrategic or Co-development Partner · 1 June 2025PHARMIDEA is the cooperation partner in the COMPETE project (Project No. 1.1.1.3/1./24/A/157), focused on comparing organ-on-chip versus traditional systems for Ozempic generic quality assessment. Project period June 2025 to May 2027, costs €873,448.
  • BMC (Biomedical Research & Study Centre)minorStrategic or Co-development Partner · 1 May 2025BMC is the Principal Investigator host institution for the DIGI-MET2D project (Project No. 1.1.1.3/1./24/A/043, costs €656,455), with Dr. Ilze Elbere as PI. Project focuses on precision metformin dosing using digital twin and gut-on-a-chip models for Type 2 Diabetes patients.
  • ESQlabsminorStrategic or Co-development Partner · 1 May 2025ESQlabs was contracted under the DIGI-MET2D project for digital twin model development, as part of the project's approach to integrating digital twin simulations with organ-on-chip technology for personalized Type 2 Diabetes treatment.
  • Institute of Solid State Physics, University of LatviaminorStrategic or Co-development Partner · 1 May 2025Listed as cooperation partner in the MIRACLE project (Project No. 1.1.1.3/1./24/A/156, €855,505, May 2025–April 2027), focused on real-time multi-modal monitoring platform for organ-on-chip models integrating optical sensors and impedance spectroscopy.
  • Dr. Maira Elksne Research GroupminorStrategic or Co-development Partner · 1 May 2025Led by Dr. Maira Elksne, this collaboration in the Real-time electrochemical detection project (Project No. 1.1.1.3/1./24/A/052, €677,328, May 2025–April 2028) aims to develop electrochemical sensor technology for continuous ATP and glucose monitoring in organ-on-chip systems.
  • KTH Royal Institute of TechnologyminorStrategic or Co-development Partner · 1 April 2024KTH Royal Institute of Technology is a project partner in the GBA-Connect project (Eureka Eurostars 5304, period April 2024–March 2026, €250,000), alongside Latvian Biomedical Research & Study Centre, Teadusmosaiik OÜ, and Fewer Moving Parts Ltd. Focus on vascularized Gut-Brain-Axis-on-chip platform.
  • Teadusmosaiik OÜminorStrategic or Co-development Partner · 1 April 2024Listed as a partner in the GBA-Connect Eurostars project (project No. 5304, €250,000, April 2024–March 2026).
  • Fewer Moving Parts LtdminorStrategic or Co-development Partner · 1 April 2024Listed as a partner in the GBA-Connect Eurostars project (project No. 5304, €250,000, April 2024–March 2026).
  • Leibniz InstituteminorStrategic or Co-development PartnerListed as a partner on the Cellbox Labs website's 'Our Partners' section. The partnership involves advancing frontiers of scientific discovery in cell research.
  • Altis BiosystemscoreStrategic or Co-development PartnerListed as a partner on the Cellbox Labs website. Altis Biosystems is referenced in the VALIDATE project as the source of high-quality primary small intestinal cells for the industrial-grade Gut-on-a-Chip platform. Also listed as a company logo partner on the Cellbox Labs website.
  • KTH Royal Institute of TechnologyminorStrategic or Co-development PartnerListed as a partner on the Cellbox Labs website. KTH is also a project partner in GBA-Connect (Eureka Eurostars project 5304), collaborating on the vascularized Gut-Brain-Axis-on-chip platform.
  • Embion Technologies SAminorStrategic or Co-development PartnerListed as a partner on the Cellbox Labs website. Embion is the project coordinator of the HARMONIS Eurostars project (6525), focused on microbiome optimization and nutrition for healthy ageing.
  • BMC (Biomedical Research Centre)minorStrategic or Co-development PartnerListed as a partner on the Cellbox Labs website. BMC (Latvian Biomedical Research & Study Centre) is a key collaborator in multiple EU projects including LoCBox, PERFORM-CHIP, PROCEX, COMPETE, VALIDATE, DIGI-MET2D, and GBA-Connect.
  • CFIminorStrategic or Co-development PartnerListed as a partner on the Cellbox Labs website 'Our Partners' section.
  • LU (University of Latvia)minorStrategic or Co-development PartnerListed as a partner on the Cellbox Labs website. University of Latvia's Institute of Solid State Physics is a project partner in the MIRACLE project and LoCBox project.
  • Max Delbrück Center for Molecular MedicineminorStrategic or Co-development PartnerListed as a partner on the Cellbox Labs website 'Our Partners' section.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Cellbox Labs competitors and assessment

Company assessment

Direct peers

  • Emulate: Emulate is the leading commercial organ-on-chip company, offering the Emulate Chip-A1 and associated instruments. Direct competitor in the same OoC product category targeting pharma and biotech customers; significantly larger and more commercially mature.
  • MIMETAS: MIMETAS provides organ-on-chip platforms (OrganoPlate) for compound screening and disease modeling, with a strong focus on high-throughput applications. Directly comparable product offering for pharma and biotech preclinical researchers.
  • CN Bio: CN Bio offers PhysioMimix organ-on-chip systems for drug discovery and disease modeling, including liver, lung, and gut models. Comparable hardware-plus-consumables OoC platform serving pharma R&D customers.
  • TissUse: TissUse develops multi-organ-chip (MOC) platforms enabling interconnection of multiple organ models. Comparable OoC technology targeting drug testing and ADME applications.
  • Hesperos: Hesperos produces human-on-a-chip multi-organ systems for toxicity and efficacy testing, particularly serving orphan disease and rare disease drug development. Comparable OoC service-and-platform model.
  • SynVivo: SynVivo offers microfluidic organ-on-chip platforms for drug delivery and toxicity studies, including tumor and BBB models. Comparable product offering and customer base in pharma and academic research.

Emerging players

  • InSphero: InSphero provides 3D cell culture models and organoids for drug discovery, with overlap in disease modeling and toxicology. Comparable target customer base, though focuses on static 3D models rather than microfluidic OoC platforms.
  • Bi/ond: Bi/ond develops organ-on-chip platforms with focus on scalable and reproducible in vitro models for pharma applications. Comparable emerging European OoC start-up with overlapping customer focus.

Broad incumbents

  • Organovo: Organovo is an early pioneer in 3D bioprinted human tissue for preclinical research and therapeutic applications. Broader incumbent in tissue engineering space with adjacent but different technology approach.

Others

  • Altis Biosystems: Altis Biosystems provides primary intestinal epithelial cell models and is a named partner of Cellbox Labs on the VALIDATE project. Adjacent ecosystem participant supplying biological inputs for Cellbox's gut-on-chip platform.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Cellbox Labs social profiles

Digital presence

Cellbox Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cellbox Labs leadership team

Management profile

Number of profiles

Profiles14 records

Cellbox Labs funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cellbox Labs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellbox Labs

What does Cellbox Labs do?

Cellbox Labs designs, mass-manufactures, and sells an integrated industrial organ-on-chip platform consisting of mass-produced COC chip devices and an automated cultivation instrument with integrated real-time microscopy, software, and proprietary pumping and gas-control systems. The company also delivers tailored contract research services covering in vitro pharmacology, disease modeling, and feasibility studies using primary cells, iPSC-derived cells, organoids, and co-cultures for pharmaceutical, biotech, and academic customers.

Is Cellbox Labs a public or private company?

Cellbox Labs is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cellbox Labs founded?

Cellbox Labs was founded in 2020. It employs 11 to 50 people.

Where is Cellbox Labs based?

Cellbox Labs is headquartered in Riga, Latvia, in the Europe region.

How does Cellbox Labs make money?

Three revenue lines are on record. Organ-on-Chip Hardware Products are the primary driver. The others are contract Research Services and EU Research Grants and Project Funding.

Who are Cellbox Labs's main competitors?

Direct peers on record are Emulate, MIMETAS, CN Bio, TissUse, Hesperos and SynVivo. Emerging players are InSphero and Bi/ond. Organovo is listed as a broad incumbent. Altis Biosystems is listed as an others.

Does Cellbox Labs have an API?

No public API is recorded for Cellbox Labs.

What industry is Cellbox Labs in?

Cellbox Labs's product category is Organ-on-chip instruments and consumables. Its primary akta.pro industry code is HLAAAGAD, Organoids & Organ-on-Chip (regenerative models), with a secondary code of HLAGAIAG, Cell Culture & Bioprocess Lab Equipment (Bioreactors, Single-Use Systems, Controllers). Its NAICS code is 334516 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FoundersTodayCellbox Labs from Latvia secures €3.3M to advance Lab-Grown Mini Organs for Drug TestingCellbox Labs, a Latvia-based biotech, raised €3.3 million in non-dilutive funding to advance its lab-grown mini-organ chips for drug testing. The capital will scale gut-on-chip models, embed sensors, and benchmark GLP-1 generics. The company cites regulatory shifts like FDA's removal of animal testing requirements as accelerating demand.ArcticstartupLatvian startup receives €3.3 million to advance organ-on-chip technologiesCellbox Labs, a Riga-based biotech, secured €3.3 million in non-dilutive funding to advance organ-on-chip technologies. The EU IPCEI Tech4Cure funding will support projects including a gut-on-chip system, sensor integration, and digital twin models. The company aims to enhance its platforms for pharmaceutical and biosimilar testing.BebeezLatvian BioTech startup Cellbox Labs lands €3.3 million for organ-on-chip innovation without the animal testing – BeBeez InternationalRiga-based Cellbox Labs secured €3.3 million in non-dilutive funding to accelerate its organ-on-chip technology. The funds, partly from EU IPCEI state aid, will support scaling gut-on-chip models, integrating sensors, benchmarking biosimilars, and developing digital twin models. The company aims to advance predictive drug testing without animal trials.BebeezLatvian startup receives €3.3 million to advance organ-on-chip technologies – BeBeez InternationalCellbox Labs, a Riga-based biotech, secured €3.3 million in non-dilutive funding to advance organ-on-chip technologies. The EU IPCEI Tech4Cure funding will support projects including a gut-on-chip system, sensor integration, and digital twin models. The company aims to enhance its platforms for pharmaceutical and biosimilar testing.AinCellbox Labs secures €3.3M funding to scale personalized gut-on-chip modelsCellbox Labs, a Latvian biotech startup, secured €3.3 million in funding for its gut-on-chip models and drug discovery. Part of the funding comes from state aid via the IPCEI 'Tech4Cure' initiative. The company will use the funds to scale personalized gut-on-chip models, integrate sensors, and develop digital twin models.Labs of Latvia“Cellbox Labs” attracts €3.3 million in fundingBiotech startup Cellbox Labs has secured €3.3 million in funding for the continued development of its organ-on-a-chip product portfolio, with part of the funding coming from the EU's Important Projects of Common European Interest (IPCEI) initiative "Tech4Cure" in the healthcare sector. The funding will support gut-on-a-chip validation for industry in collaboration with Altis Biosystems, personalized gut-on-a-chip model testing, development of a pancreas-on-a-chip for GLP-1 generic drug evaluation, and integration of sensors for real-time O₂ and pH data readings. The company is also working with ESQlabs and MPSlabs to develop high-precision digital twin models for its in vitro systems, with the aim of supporting biosimilar assessment and advancing personalized medicine applications.AinLatvian biotech Cellbox Labs raises €935k in a pre-seed round – AIN.CapitalLatvian biotech startup Cellbox Labs raised €935,000 in a pre-seed funding round led by Buildit VC with participation from a syndicate of 12 LatBAN angels. The company plans to use the capital to finalize its automated organ-on-chip cultivation platform and initiate sales. Additionally, Cellbox Labs intends to showcase the technology at upcoming industry summits in Seattle and Milan.LinkedInBuildit Digest: Autumn’s Harvest & Future Winds of GrowthBuildit Accelerator is experiencing growth with new startup additions to its portfolio, such as Emotsy and Cellbox Labs, while preparing for future expansion and a new fund. Cellbox Labs recently won an award at the Latvian Startup Awards for its innovative biotechnology solutions. The organization is also planning a significant relocation and has appointed a new financial mentor to support its startups.